Tempus

Lab workers at Tempus pushed for unionization citing workplace safety concerns and stagnant wages. Crain's Chicago Business reported employees want more say in workplace safety and better pay. Tempus went public in June 2024 at a $6.1B valuation and has been named to Forbes AI 50 list for its precision medicine work.

FDA awarded Tempus breakthrough designation status for an AI algorithm to predict AFib from a normal ECG. Tempus also received FDA approval for ECG-Low EF software to identify patients with low left ventricular ejection fraction. The company works in regulated clinical settings, balancing R&D speed with validation, and supports FDA partial 510(k) exemption proposals for AI medical devices.

Laid off 5% in 2023, another 7% in 2024. Security breaches damaged reputation. Cost cutting mode.